Medical - Care Facilities
Compare Stocks
4 / 10Stock Comparison
ARDT vs UNH vs CVS vs HCA
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Care Facilities
ARDT vs UNH vs CVS vs HCA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Care Facilities |
| Market Cap | $1.41B | $335.60B | $111.40B | $95.95B |
| Revenue (TTM) | $6.43B | $449.71B | $407.90B | $75.60B |
| Net Income (TTM) | $134M | $12.04B | $2.93B | $6.78B |
| Gross Margin | 60.5% | 18.8% | 13.9% | 41.5% |
| Operating Margin | 8.9% | 4.2% | 1.5% | 15.8% |
| Forward P/E | 8.7x | 20.2x | 12.2x | 14.2x |
| Total Debt | $2.26B | $78.39B | $93.59B | $50.20B |
| Cash & Equiv. | $710M | $24.36B | $8.51B | $1.04B |
ARDT vs UNH vs CVS vs HCA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 24 | May 26 | Return |
|---|---|---|---|
| Ardent Health Partn… (ARDT) | 100 | 55.3 | -44.7% |
| UnitedHealth Group … (UNH) | 100 | 64.2 | -35.8% |
| CVS Health Corporat… (CVS) | 100 | 144.7 | +44.7% |
| HCA Healthcare, Inc. (HCA) | 100 | 118.2 | +18.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ARDT vs UNH vs CVS vs HCA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ARDT is the clearest fit if your priority is value.
- Lower P/E (8.7x vs 14.2x)
UNH is the clearest fit if your priority is growth exposure.
- Rev growth 11.8%, EPS growth -14.7%, 3Y rev CAGR 11.4%
- 11.8% revenue growth vs ARDT's 6.0%
CVS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- Lower volatility, beta 0.05, current ratio 0.84x
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Beta 0.05 vs ARDT's 1.40, lower leverage
HCA is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 450.5% 10Y total return vs UNH's 220.6%
- 9.0% margin vs CVS's 0.7%
- 11.3% ROA vs CVS's 1.1%, ROIC 19.9% vs 5.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.8% revenue growth vs ARDT's 6.0% | |
| Value | Lower P/E (8.7x vs 14.2x) | |
| Quality / Margins | 9.0% margin vs CVS's 0.7% | |
| Stability / Safety | Beta 0.05 vs ARDT's 1.40, lower leverage | |
| Dividends | 3.1% yield, vs UNH's 2.4%, (1 stock pays no dividend) | |
| Momentum (1Y) | +34.7% vs ARDT's -30.5% | |
| Efficiency (ROA) | 11.3% ROA vs CVS's 1.1%, ROIC 19.9% vs 5.0% |
ARDT vs UNH vs CVS vs HCA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ARDT vs UNH vs CVS vs HCA — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HCA leads in 3 of 6 categories
ARDT leads 1 • CVS leads 1 • UNH leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
HCA leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 70.0x ARDT's $6.4B. HCA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to CVS's 0.7%. On growth, ARDT holds the edge at +7.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $6.4B | $449.7B | $407.9B | $75.6B |
| EBITDAEarnings before interest/tax | $733M | $23.2B | $10.5B | $15.5B |
| Net IncomeAfter-tax profit | $134M | $12.0B | $2.9B | $6.8B |
| Free Cash FlowCash after capex | $214M | $19.7B | $7.4B | $7.7B |
| Gross MarginGross profit ÷ Revenue | +60.5% | +18.8% | +13.9% | +41.5% |
| Operating MarginEBIT ÷ Revenue | +8.9% | +4.2% | +1.5% | +15.8% |
| Net MarginNet income ÷ Revenue | +2.1% | +2.7% | +0.7% | +9.0% |
| FCF MarginFCF ÷ Revenue | +3.3% | +4.4% | +1.8% | +10.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.0% | +2.0% | +6.2% | +6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.4% | +0.7% | +63.1% | +44.6% |
Valuation Metrics
ARDT leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 10.3x trailing earnings, ARDT trades at a 84% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, ARDT's 6.2x EV/EBITDA is more attractive than UNH's 16.7x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $1.4B | $335.6B | $111.4B | $95.9B |
| Enterprise ValueMkt cap + debt − cash | $3.0B | $389.6B | $196.5B | $145.1B |
| Trailing P/EPrice ÷ TTM EPS | 10.29x | 27.95x | 62.81x | 15.12x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.65x | 20.19x | 12.19x | 14.19x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.72x |
| EV / EBITDAEnterprise value multiple | 6.17x | 16.70x | 13.11x | 9.37x |
| Price / SalesMarket cap ÷ Revenue | 0.22x | 0.75x | 0.28x | 1.27x |
| Price / BookPrice ÷ Book value/share | 0.83x | 3.31x | 1.47x | — |
| Price / FCFMarket cap ÷ FCF | 5.47x | 20.88x | 14.27x | 12.47x |
Profitability & Efficiency
HCA leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
UNH delivers a 11.5% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $4 for CVS. UNH carries lower financial leverage with a 0.77x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARDT's 1.34x. On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs CVS's 5/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +8.0% | +11.5% | +3.9% | — |
| ROA (TTM)Return on assets | +2.6% | +3.9% | +1.1% | +11.3% |
| ROICReturn on invested capital | +7.5% | +9.2% | +5.0% | +19.9% |
| ROCEReturn on capital employed | +7.9% | +9.7% | +6.1% | +27.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 5 | 7 |
| Debt / EquityFinancial leverage | 1.34x | 0.77x | 1.24x | — |
| Net DebtTotal debt minus cash | $1.6B | $54.0B | $85.1B | $49.2B |
| Cash & Equiv.Liquid assets | $710M | $24.4B | $8.5B | $1.0B |
| Total DebtShort + long-term debt | $2.3B | $78.4B | $93.6B | $50.2B |
| Interest CoverageEBIT ÷ Interest expense | 6.36x | 4.71x | 2.11x | 5.37x |
Total Returns (Dividends Reinvested)
HCA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HCA five years ago would be worth $20,974 today (with dividends reinvested), compared to $6,152 for ARDT. Over the past 12 months, CVS leads with a +34.7% total return vs ARDT's -30.5%. The 3-year compound annual growth rate (CAGR) favors HCA at 16.3% vs ARDT's -15.0% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +14.4% | +10.6% | +10.6% | -8.6% |
| 1-Year ReturnPast 12 months | -30.5% | -3.2% | +34.7% | +19.7% |
| 3-Year ReturnCumulative with dividends | -38.5% | -19.9% | +36.6% | +57.4% |
| 5-Year ReturnCumulative with dividends | -38.5% | -2.6% | +17.0% | +109.7% |
| 10-Year ReturnCumulative with dividends | -38.5% | +220.6% | +3.5% | +450.5% |
| CAGR (3Y)Annualised 3-year return | -15.0% | -7.1% | +11.0% | +16.3% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than ARDT's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs ARDT's 63.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.40x | 0.59x | 0.05x | 0.29x |
| 52-Week HighHighest price in past year | $15.48 | $395.52 | $88.63 | $556.52 |
| 52-Week LowLowest price in past year | $8.07 | $234.60 | $58.35 | $330.00 |
| % of 52W HighCurrent price vs 52-week peak | +63.8% | +93.5% | +98.5% | +77.1% |
| RSI (14)Momentum oscillator 0–100 | 46.6 | 75.9 | 69.3 | 30.8 |
| Avg Volume (50D)Average daily shares traded | 382K | 7.9M | 7.4M | 1000K |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ARDT as "Buy", UNH as "Buy", CVS as "Buy", HCA as "Buy". Consensus price targets imply 34.9% upside for ARDT (target: $13) vs 4.2% for UNH (target: $385). For income investors, CVS offers the higher dividend yield at 3.06% vs HCA's 0.69%.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $13.33 | $385.43 | $95.20 | $527.45 |
| # AnalystsCovering analysts | 12 | 52 | 41 | 46 |
| Dividend YieldAnnual dividend ÷ price | — | +2.4% | +3.1% | +0.7% |
| Dividend StreakConsecutive years of raises | 1 | 25 | 0 | 5 |
| Dividend / ShareAnnual DPS | — | $8.70 | $2.67 | $2.94 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% | 0.0% | +10.5% |
HCA leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ARDT leads in 1 (Valuation Metrics). 1 tied.
ARDT vs UNH vs CVS vs HCA: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ARDT or UNH or CVS or HCA a better buy right now?
For growth investors, UnitedHealth Group Incorporated (UNH) is the stronger pick with 11.
8% revenue growth year-over-year, versus 6. 0% for Ardent Health Partners, LLC (ARDT). Ardent Health Partners, LLC (ARDT) offers the better valuation at 10. 3x trailing P/E (8. 7x forward), making it the more compelling value choice. Analysts rate Ardent Health Partners, LLC (ARDT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ARDT or UNH or CVS or HCA?
On trailing P/E, Ardent Health Partners, LLC (ARDT) is the cheapest at 10.
3x versus CVS Health Corporation at 62. 8x. On forward P/E, Ardent Health Partners, LLC is actually cheaper at 8. 7x.
03Which is the better long-term investment — ARDT or UNH or CVS or HCA?
Over the past 5 years, HCA Healthcare, Inc.
(HCA) delivered a total return of +109. 7%, compared to -38. 5% for Ardent Health Partners, LLC (ARDT). Over 10 years, the gap is even starker: HCA returned +450. 5% versus ARDT's -38. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ARDT or UNH or CVS or HCA?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Ardent Health Partners, LLC's 1. 40β — meaning ARDT is approximately 2665% more volatile than CVS relative to the S&P 500. On balance sheet safety, UnitedHealth Group Incorporated (UNH) carries a lower debt/equity ratio of 77% versus 134% for Ardent Health Partners, LLC — giving it more financial flexibility in a downturn.
05Which is growing faster — ARDT or UNH or CVS or HCA?
By revenue growth (latest reported year), UnitedHealth Group Incorporated (UNH) is pulling ahead at 11.
8% versus 6. 0% for Ardent Health Partners, LLC (ARDT). On earnings-per-share growth, the picture is similar: HCA Healthcare, Inc. grew EPS 29. 0% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, UNH leads at 11. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ARDT or UNH or CVS or HCA?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCA leads at 15. 8% versus 2. 6% for CVS. At the gross margin level — before operating expenses — ARDT leads at 97. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ARDT or UNH or CVS or HCA more undervalued right now?
On forward earnings alone, Ardent Health Partners, LLC (ARDT) trades at 8.
7x forward P/E versus 20. 2x for UnitedHealth Group Incorporated — 11. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARDT: 34. 9% to $13. 33.
08Which pays a better dividend — ARDT or UNH or CVS or HCA?
In this comparison, CVS (3.
1% yield), UNH (2. 4% yield), HCA (0. 7% yield) pay a dividend. ARDT does not pay a meaningful dividend and should not be held primarily for income.
09Is ARDT or UNH or CVS or HCA better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, ARDT: -38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ARDT and UNH and CVS and HCA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ARDT is a small-cap deep-value stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; HCA is a mid-cap deep-value stock. UNH, CVS, HCA pay a dividend while ARDT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.